Robert Li, a dedicated entrepreneur, founded LTZ Therapeutics in 2021, assuming the role of Chief Executive Officer (CEO). Robert is also a seasoned drug developer with 15+ years of industry experience in translational research and development, within therapeutic areas of immunology, oncology, and cancer immunology. He held multiple leadership roles such as biotech executive, cross functional team lead and immunology therapeutic area lead-safety assessment at renowned global pharmaceutical companies like Bristol-Myers Squibb, Genentech, and Vir Biotechnology. He leads/supports the achievement of critical developmental milestones for over 10 small and large molecules, including IND filings, pivotal trials, NDA/BLA submissions, and global regulatory interactions. He is frequently invited as speaker, chair, and/or panelist at prestigious international conferences, including AACR-FDA workshop, CDE workshop, SOT annual meeting, BioSafe annual meeting, Bispecific summit, JP Morgan regional expert meeting, and the BiG meeting, among others.

Dr. Li received a Ph.D. in immunotoxicology from the University of Toronto, followed by a postdoctoral training at Hoffmann-La Roche. In addition to his responsibilities at LTZ Therapeutics, Robert served as the President for the SOT Biotechnology Specialty Section for the years 2021-2022, where he strived to contribute to the advancement of the field. He is also the SOT award recipient of the Outstanding Young Immunotoxicologist in 2017 and the Outstanding Young Investigator in Biotechnology in 2018.